PROM1 and colorectal carcinoma: Thus, CD133 staining patterns were found to differ in CRC between the use of AC133 (Miltenyi Biotech) and Ab19898 (Abcam) monoclonal antibodies[49] and among the application of anti-CD133 (Cell Signalling), AC133 (Miltenyi Biotech), and polyclonal anti-CD133 (Santa Cruz Biotechnology) antibodies[29].